#ohtuvayre

#ohtuvayre

Merck has agreed to acquire Verona Pharma for $10 billion, gaining access to its first-in-class drug Ohtuvayre, which treats chronic obstructive pulmonary disease (COPD). This acquisition is crucial as Merck seeks assets amid an impending revenue drop from its top product losing patent protection.